CAU Scholar's Space: Shin, So Young

Detailed Information

Shin, So Young (신소영)

대학원 (글로벌혁신신약학과)

Research Area

Tel 02-820-5947
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

pharmacokinetics:12||Pharmacokinetics:10||LCMS/MS:6||MS:5||LCMS:5||bioavailability:4||Population pharmacokinetic model:3||sustained release:3||population pharmacokinetic modeling:3||fimasartan:3||population pharmacokinetics:3||Semaglutide:2||telacebec:2||herbal medicine:2||toxicokinetics:2||adiposederived stem cells:2||in vitroin vivo correlation:2||Baclofen:2||3T3L1:2||Tissue distribution:2||safety:2||drugdrug interaction:2||Angiotensin II receptor blocker:2||Bioavailability:2||Brain distribution:2||Fimasartan:1||Fructus arctii:1||GLP1 analogs:1||GLP1 receptor agonist:1||GLP1 receptor agonists:1||Glucagonlike peptide1:1||Glucocorticoid receptor:1||Glycidamide:1||Guipi Decoction:1||HFDINDUCED OBESE MICE:1||Hyangsayukgunjatang:1||Hydroxyproline:1||Hydroxypropyl methylcellulose:1||Hypertension:1||Hypertension cardiovascular activity:1||Hypothalamus:1||In vitro–in vivo correlation:1||In vitro in vivo correlation:1||In vitroin vivo correlation:1||Interspecies scaling:1||Intraindividual variability:1||Intramuscular injection:1||Ketoprofen:1||LC/MS/MS:1||Lifitegrast:1||Lipin1:1||Liraglutide:1||Loganin:1||Maternalfetal transfer:1||Mechanismbased modeling:1||Megestrol acetate:1||Milk secretion:1||Modelbased drug development:1||Modeling and simulation:1||Nardostachys jatamansi:1||Nuclear factorkappa B:1||Ocular tissue:1||Pglycoprotein:1||PDECGF:1||PDGFC:1||Pharmacodynamics:1||Physiologically based pharmacokinetic model:1||Population pharmacokinetics pharmacodynamics:1||Praline:1||Proinflammatory cytokines:1||Proliferation:1||Q203:1||Rutin:1||SADAPT:1||Serpinel:1||Sipjeondaebotang:1||Sustainedrelease:1||Tacrolimus:1||Telacebec:1||Tuberculosis:1||UV filtering agent:1||[6]gingerol:1||absorption:1||absorption window:1||aceclofenac:1||acyclovir:1||animal to human scaling:1||antituberculosis:1||baclofen:1||benzophenone3:1||capsaicin:1||controlled release formulations:1||design of experiments:1||desoxonarchinol A:1||diclofenac:1||distribution:1||donepezil:1||doxorubicin:1||drug delivery system:1||enterohepatic recirculation:1||erlotinib:1||esomeprazole:1||extended release formulation:1||floating system:1||gastric ulcer:1||gefitinib:1||gemcitabine:1||gimeracil:1||hAMSCs:1||hair growth:1||herbdrug interaction:1||hexamethylenetetramine:1||in situ singlepass perfusion:1||in vitroin vivo correlation (IVIVC):1||intestinal permeability:1||level A IVIVC:1||lipidbased formulation:1||lixisenatide:1||loxoprofen:1||lymphatic transport:1||lysophosphatidic acid:1||metabolism:1||metabolite profiling:1||methenamine:1||miR210:1||minoxidil:1||mitogenic effects:1||mixture design:1||multiple ascending doses:1||nafamostat:1||olaparib:1||phase 1 trial:1||piperine:1||plasma:1||prediction of in vivo pharmacokinetics:1||preservative:1||reactive oxygen species:1||regional absorption:1||riboflavin:1||siRNA:1||sildenafil:1||sitedependent dissolution:1||solid SNEDDS:1||solubility:1||spray drying:1||tolerability:1||transdermal absorption:1||tuberculosis:1||type 2 diabetes:1||3D printing:1||validation:1||5FU:1||AMPK:1||ARCTIGENIN:1||Acetylcarnitine:1||Acrylamide:1||Acute pancreatitis:1||Adipogenic differentiation:1||Adiposederived stem cells:1||Allometric scaling:1||Angiotensin receptor blocker:1||Arctigenin:1||Arginine:1||BCS class IV:1||Bawu Decoction:1||Beagle dog:1||COVID19:1||CXCL1:1||Circadian rhythm:1||Citrulline:1||Cynomolgus monkey:1||Design of experiment:1||Dry eye disease:1||Enterohepatic recirculation:1||Extendedrelease formulation:1||

RSS_1.0 RSS_2.0 ATOM_1.0

84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE